{
    "Trade/Device Name(s)": [
        "N Antisera to Human Complement Factors (C3c, C4)"
    ],
    "Submitter Information": "Dade Behring Inc.",
    "510(k) Number": "K050665",
    "Predicate Device Reference 510(k) Number(s)": [
        "K860894"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CZW",
        "DBI"
    ],
    "Summary Letter Date": "May 2, 2005",
    "Summary Letter Received Date": "March 15, 2005",
    "Submission Date": "March 14, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.5240"
    ],
    "Regulation Name(s)": [
        "Complement components immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Complement C3/C3c",
        "Complement C4/C4c"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Heparinized plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "BN Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Immunonephelometry"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for N Antisera to Human Complement Factors (C3c, C4) for quantitative immunonephelometric determination of complement factors in serum and plasma",
    "Indications for Use Summary": "In vitro diagnostic reagents for the quantitative determination of complement factors (C3/C3c and C4/C4c) in human serum or heparinized or EDTA plasma by means of immunonephelometry on the BN Systems as an aid in the diagnosis of immunologic disorders associated with complement C3 or C4 protein.",
    "fda_folder": "Immunology"
}